Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $185 to $190.
June 18, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on AbbVie and increased the price target from $185 to $190, indicating a positive outlook on the stock.
The increase in price target from $185 to $190 by Piper Sandler, along with the maintained Overweight rating, suggests a positive sentiment towards AbbVie's stock. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100